| Ytd | -26.21% | |
| 1y | 28.49% |
| Open | 1.00 | Prev Close | 1.00 | Low | 0.98 | High | 1.01 | Mkt Cap | 73.58M |
| Vol | 36.73K | Avg Vol | 1.49M | EPS | -0.24 | P/E | -4.17 | Forward P/E | -0.80 |
| Beta | 1.75 | Short Ratio | 1.07 | Inst. Own | 24.53% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 11-12 | 50-d Avg | 1.18 | 200-d Avg | 1.31 | 1yr Est | 6.50 |
CGTX News
PURCHASE, N. Y. , July 13, 2026 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc. (Nasdaq: CGTX), a c
Cognition Therapeutics is currently prioritizing zervimesine for DLB psychosis. This is after the FD
Gainers Pulsenmore (NASDAQ:PLSM) shares moved upwards by 160.5% to $8.88 during Wednesday's reg
Cognition Therapeutics, Inc., (the "Company" or "Cognition") (NASDAQ:CGTX), a clinic
- Zervimesine Would be the First Long-term, Durable Treatment Option with an Impact on Underlying Di
PURCHASE, N.Y., June 16, 2026 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc., (the “Company” or “C
PURCHASE, N.Y., June 01, 2026 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc. (Nasdaq: CGTX), a cli
- Positive Discussion on Path Forward for Registrational Program - PURCHASE, N.Y., May 21, 2026 (GLO
PURCHASE, N.Y., May 14, 2026 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc., (the “Company” or “Co
Meeting with FDA Division of Psychiatry scheduled for May 2026 expected to inform registrational pla
Cognition Therapeutics, Inc. (NASDAQ: CGTX - Get Free Report) CEO Lisa Ricciardi bought 9,175 shares
Cognition Therapeutics, Inc. (NASDAQ: CGTX - Get Free Report) CFO John Brendan Doyle acquired 10,000
Cognition Therapeutics (NASDAQ: CGTX) executives told investors at the Needham conference that the c
PURCHASE, N.Y., April 07, 2026 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc. (Nasdaq: CGTX), a cl
Advancing Zervimesine (CT1812) towards late-stage trials for dementia with Lewy bodies (DLB) psycho
Cognition Therapeutics (NASDAQ: CGTX) used its fourth-quarter and full-year 2025 earnings call to ou
Cognition Therapeutics, Inc. (CGTX) Q4 2025 Earnings Call Transcript
-Advancing zervimesine clinical development in DLB psychosis – - Meeting with FDA Division of Psych
PURCHASE, N.Y., March 23, 2026 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc. (Nasdaq: CGTX), a cl
PURCHASE, N.Y., March 17, 2026 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc., (the “Company” or “
We believe regulatory strategy expedites development of potential first treatment to address DLB psy
Companies Reporting Before The Bell • bluebird bio (NASDAQ:BLUE) is likely to report quarterly loss
Shares of Airspan Networks Holdings Inc. (NASDAQ: MIMO) shares rose sharply during Wednesday’s sessi
On Wednesday, 329 companies hit new 52-week lows.
Gainers